| 0.43 0 (0%) | 09-13 13:09 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.55 | 1-year : | 0.61 |
| Resists | First : | 0.47 | Second : | 0.52 |
| Pivot price | 0.44  |
|||
| Supports | First : | 0.37 | Second : | 0.31 |
| MAs | MA(5) : | 0.43 | MA(20) : | 0.44 |
| MA(100) : | 0.56 |
MA(250) : | 0.95 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 4.7 | D(3) : | 4.7 |
| RSI | RSI(14): 48 | |||
| 52-week | High : | 3.09 | Low : | 0 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CWBR ] has closed above bottom band by 40.2%. Bollinger Bands are 57.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 19 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.43 - 0.43 | 0.43 - 0.43 |
| Low: | 0.42 - 0.43 | 0.43 - 0.43 |
| Close: | 0.43 - 0.43 | 0.43 - 0.43 |
CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.
Sat, 17 Jun 2023
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - CWBR, FOCS, PTRS, ARNC - PR Newswire
Tue, 23 May 2023
Nasdaq Down 1%; AutoZone Posts Downbeat Sales - Markets Insider
Tue, 23 May 2023
CohBar Stock Doubles: Company Agrees To Merge With Morphogenesis To Advance Late-Stage Oncology Candidates - Yahoo Finance
Mon, 22 May 2023
Morphogenesis, Inc. announced that it expects to receive $15 million in funding from CohBar, Inc. - Marketscreener.com
Tue, 07 Jun 2022
CohBar to Participate at Upcoming Conferences in June 2022 - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 15 (%) |
| Held by Institutions | 6.2 (%) |
| Shares Short | 15 (K) |
| Shares Short P.Month | 29 (K) |
| EPS | -4.37 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.26 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -48.4 % |
| Return on Equity (ttm) | -84 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.48 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.1 |
| PEG Ratio | 0 |
| Price to Book value | 0.13 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.16 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|